Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma

• DOI: 10.1007/s00005-016-0442-6
• Publication Date: 2017-01-12T13:52:03Z
• Authors: Aleksandra Butrym; Piotr Łacina; Justyna Rybka; Monika Chaszczews...; Grzegorz Mazur; Katarzyna Bogunia...
• Keywords: IRF4; Cereblon

Multiple myeloma (MM) is a plasma-cell malignancy derived from an early precursor of the B-cell lineage characterised by bone-marrow infiltration, lytic bone lesions, and presence monoclonal protein in serum and/or urine. Interferon regulatory factor 4 (IRF4) critical transcriptional regulator development function that required during immune response for lymphocyte activation generation immunoglobulin-secreting plasma cells. Immunomodulatory drugs, derivatives thalidomide, are commonly used therapy against MM. They known to target called cereblon (CRBN); however, exact mechanism remains unknown. The present study aimed assess association two (rs12203592 rs872071) polymorphisms within IRF4 gene (rs711613 rs1045433) CRBN with MM susceptibility, progression, treatment. For this purpose, 144 patients 126 healthy individuals were genotyped alleles. (rs872071) G allele was more frequently detected than (OR 1.78; P = 0.034), relationship especially pronounced women 2.83; 0.012). (rs711613) A allele-carriers better responders treatment (P 0.012), particular thalidomide including 0.023). These results underline prognostic significance